Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology
Syndax published Phase 1/2 SAVE trial data for Revuforj in combination with decitabine/cedazuridine and venetoclax in relapsed/refractory AML in the Journal of Clinical Oncology. The all-oral regimen achieved an 88% overall response rate and 60% CR/CRh rate in a heavily pretreated cohort, with 80% of responders achieving MRD negativity.
Key figures
- Drug Name
- Revuforj (revumenib)
- Phase Of Trial
- Phase 1/2
- Orr
- 88%
- Crc rate
- 71%
- Median os
- 14 months
- Cr crh rate
- 60%
- Mrd negativity
- 80%
- Transplant rate
- 45%
- Venetoclax naive cr crh
- 70%
- Venetoclax exposed cr crh
- 50%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.